May 27, 2021
Today, Oisín Biotechnologies, a well-known developer of senolytics, drugs that destroy harmful senescent cells, has announced that it has more than doubled its total funding through an oversubscribed round. This has taken its total funding from $4.5 million to $9.5 million. Why we Age: Cellular SenescenceAs your body ages, more of your cells become senescent....
October 22, 2019
We're continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. John Lewis of Oisin Biotechnologies discussed senolytics, which are drugs that kill senescent cells. He explained the differences between healthy...
October 17, 2018
Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights. Dr. Oliver Medvedik, LEAF vice president and Director of...
October 11, 2018
Senolytics are the first therapies that directly target an aging process in order to delay or prevent age-related diseases, and they are now in human trials. Today, we think that it is the ideal time to have a look at how they work and what companies are involved. Senescent cells and aging As we get...
September 21, 2018
Today, we would like to share a talk given by Stephen Hilbert, President of Oisin Biotechnologies, in which he discusses treating aging and cancer by removing harmful senescent cells. On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part...
May 25, 2018
BRINGING REJUVENATION BIOTECHNOLOGY AND INVESTORS TOGETHER At the Frederick P. Rose Auditorium, Cooper Union in New York City, we will be hosting a special one-day conference focused on aging research and biotech investment. Developing therapies from initial concepts, through clinical testing, and ultimately to market takes a pipeline, and right now, that pipeline is being...
